JNY Stock Overview
A clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
JW (Cayman) Therapeutics Co. Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.20 |
| 52 Week High | HK$0.33 |
| 52 Week Low | HK$0.18 |
| Beta | 2.16 |
| 11 Month Change | -14.35% |
| 3 Month Change | 2.07% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -11.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| JNY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.5% | -2.5% | -1.0% |
| 1Y | n/a | -21.3% | -0.5% |
Return vs Industry: Insufficient data to determine how JNY performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how JNY performed against the German Market.
Price Volatility
| JNY volatility | |
|---|---|
| JNY Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: JNY's share price has been volatile over the past 3 months.
Volatility Over Time: JNY's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 398 | James Li | www.jwtherapeutics.com |
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People’s Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers.
JW (Cayman) Therapeutics Co. Ltd Fundamentals Summary
| JNY fundamental statistics | |
|---|---|
| Market cap | €85.92m |
| Earnings (TTM) | -€98.11m |
| Revenue (TTM) | €22.21m |
3.9x
P/S Ratio-0.9x
P/E RatioIs JNY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JNY income statement (TTM) | |
|---|---|
| Revenue | CN¥173.86m |
| Cost of Revenue | CN¥85.64m |
| Gross Profit | CN¥88.22m |
| Other Expenses | CN¥856.22m |
| Earnings | -CN¥768.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.90 |
| Gross Margin | 50.74% |
| Net Profit Margin | -441.74% |
| Debt/Equity Ratio | 15.6% |
How did JNY perform over the long term?
See historical performance and comparison